Trade ALZN stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
Alzamend Neuro, Inc. (ALZN) is trading at US$1.82, up 2.25% today as of Sep 16, 12:04 EDT. The company has a market capitalisation of US$7.47M. Over the past 52 weeks, ALZN has traded between US$0.84 and US$2.68. On Syfe you can trade ALZN with $0 commission and add it to your watchlist.
| Previous close | US$1.78 |
|---|---|
| Market cap | US$7.47M |
| 52-week range | US$0.84 – US$2.68 |
| Volume | 228.43K |
| Exchange | US |
Add to Watchlist
Set Price Alert
Alzamend Neuro, Inc.
Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which is in Phase II clinical trial, and delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bipolar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders, and AL002, which completed preclinical stage, and uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. The company was founded on February 26, 2016 by Milton C. Ault, III and is headquartered in Atlanta, GA.
Year: 2021
Alzamend Neuro, Inc. (ALZN) stock is trading at US$1.82, +2.25% from the previous close of US$1.78.
The market cap for Alzamend Neuro, Inc. (ALZN) stock is approximately US$7.47M.
The 52-week high for Alzamend Neuro, Inc. (ALZN) stock is US$2.68.
The 52-week low for Alzamend Neuro, Inc. (ALZN) stock is US$0.84.
Alzamend Neuro, Inc. (ALZN) does not currently pay a dividend.
Stay on top of ALZN
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
Popular Stocks in Singapore
